Strategies for the intracellular delivery of nanoparticles

Purpose: Nanoparticles (NPs) are increasingly used as contrast agents, therapeutics, and delivery vehicles, but their effective delivery into cells and to specific subcellular organelles remains a major challenge. The review addresses fundamental barriers to intracellular NP delivery—plasma membrane, endosomal entrapment, cytoplasmic transport, and nuclear targeting—and summarizes strategies developed to overcome them.

Hypothesis: No formal experimental hypothesis. Central thesis: intracellular delivery of NPs is governed by physicochemical properties (size, shape, surface chemistry, charge) and cellular uptake/trafficking pathways; rational design of physical and biochemical delivery strategies can improve cytosolic, organelle-specific, and nuclear delivery for imaging and therapy.

Aims: Discuss fundamental challenges of delivering nanoparticles into cells and to targeted organelles. - Summarize physical delivery strategies: microinjection and electroporation. - Summarize biochemical delivery strategies: cationic coatings, cell-penetrating peptides, ligand-mediated internalization, and biodegradable carriers. - Review mechanisms of endocytosis, endosomal escape, cytoplasmic transport, and subcellular targeting. - Highlight technical limitations and provide future outlook.

Delivery system: Inorganic NPs: gold, silver, copper, iron oxides, quantum dots, silica, layered double hydroxide, calcium phosphate. - Organic NPs: liposomes, polymer micelles, polymer nanoparticles, dendrimers, carbon nanotubes, viral nanoparticles. - Payloads: contrast agents, drugs, peptides, proteins, siRNA, plasmid DNA, oligonucleotides. - Targeting/functionalization: antibodies and fragments (Fab′, ScFv, nanobody), proteins (transferrin, EGF, NGF), peptides (RGD, Tat, penetratin, RALA-like), small molecules (folate, LHRH), aptamers, cationic lipids/polymers (lipofectamine, PEI, chitosan), pH-sensitive peptides (HA2), nuclear localization signals. - Delivery strategies: microinjection, electroporation, cationic coatings, cell-penetrating peptides (CPPs), receptor-mediated endocytosis, biodegradable PLGA carriers.

Approach: Tutorial review of in vitro, ex vivo, and some in vivo literature; no primary experiments. Discusses cell lines such as HeLa, HEK293, COS-7, NIH3T3, A549, MDA-MB-231, osteoblasts, Xenopus embryos, and mouse embryos. Disease contexts include cancer, gene therapy, lysosomal storage disorders, and developmental biology. The review focuses on mechanistic principles and representative examples rather than clinical trials.

Key methods: Review-level synthesis of: - NP characterization: size, shape, surface charge, ligand density, aggregation state. - Cellular uptake and trafficking: fluorescence microscopy, confocal microscopy, flow cytometry, TEM, organelle trackers. - Endosomal escape: pH-sensitive peptides, proton-sponge effect, cationic polymer buffering. - Subcellular targeting: nuclear localization signals, mitochondrial targeting, cytoskeletal tracking. - Physical delivery: microinjection, electroporation, electromigration. - Biochemical delivery: cationic liposomes, PEI, CPPs, ligand-receptor internalization, biodegradable PLGA carriers.

Key results: Representative findings from cited literature: - Microinjection of PEG- and NLS-coated quantum dots resulted in active nuclear accumulation; microinjected QD–protein conjugates distributed homogeneously in cytoplasm rather than punctate endosomal patterns. - Up to 5 × 10⁹ quantum dots could be microinjected into Xenopus embryos without developmental abnormality; QDs remained monodisperse and photostable for up to 4 days. - Electroporation of quantum dots produced aggregates up to 500 nm in diameter; BSA cross-linking did not prevent aggregation, suggesting electric-field-induced aggregation. - Tat-HA2 fusogenic peptide delivered gold nanoparticles into NIH3T3 fibroblasts for actin imaging. - PLGA nanospheres (~104.5 ± 7.8 nm) delivered protein-conjugated quantum dots; acid-triggered charge change enabled endosomal escape, followed by polymer degradation and release of active-targeting QDs. - Folate targeting delivered polymer, gold, magnetic, and semiconductor nanocrystals selectively into cancer cells. - Transferrin, EGF, NGF, RGD, and aptamers enabled receptor-mediated NP internalization in various cell models.

Interpretation: Intracellular NP delivery remains primitive: quantitative descriptions of uptake kinetics, mechanisms, and trajectories are lacking, and rational design is hindered by incomplete understanding of nano–bio interactions. The authors argue that next-generation NPs should be application-specific and may require dynamically triggered or activated functions. Advances in synthetic and materials chemistry, combined with deeper cell biology, are expected to enable multifunctional NPs for safe and effective intracellular delivery.

Limitations: Review article; no primary data. - Microinjection: low throughput, technically demanding, expensive (~$40,000 per device), only in vitro/ex vivo. - Electroporation: requires specialized equipment, works best with suspended cells, can cause cell death and NP aggregation. - Cationic coatings/polymers: cytotoxicity, poor stability in biological buffers, aggregation. - CPP-mediated uptake: intracellular fate depends on cargo, cell line, NP size, and surface chemistry; endosomal trapping common. - Ligand-mediated targeting: receptor–ligand complexes can internalize via multiple endocytic routes, complicating control. - Endosomal escape remains inefficient; cytoplasmic transport and subcellular targeting are poorly understood. - Imaging limitations: TEM requires fixation and only detects electron-dense materials; fluorescence microscopy has limited resolution. - NP–cell interactions are dynamic and heterogeneous; results are difficult to generalize across systems.